EZH2 and neoplasm: Using independent mouse models representing NEPC generated through co-deletion of Pten and Rb1(3) or Pten and Tp53 (58), along with a human NEPC model (37) we demonstrated that monotherapy with EZH2 or PI3K/mTOR inhibitor provided limited anti-tumor benefit in both intact and castrate settings.